The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy
Open accessAbstract
Adoptive transfer of antitumor lymphocytes has gained intense interest in the field of cancer therapeutics over the past two decades. Human natural killer (NK) cells are a promising source of lymphocytes for anticancer immunotherapy. NK cells are part of the innate immune system and exhibit potent antitumor activity without need for human leukocyte antigen matching and without prior antigen exposure. Moreover, the derivation of NK cells from pluripotent stem cells could provide an unlimited source of lymphocytes for off-the-shelf therapy. To date, most studies on hematopoietic cell development from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) have used incompletely defined conditions and been on a limited scale. Here, we have used a two-stage culture system to efficiently produce NK cells from hESCs and iPSCs in the absence of cell sorting and without need for xenogeneic stromal cells. This novel combination of embryoid body formation using defined conditions and membrane-bound interleukin 21-expressing artificial antigen-presenting cells allows production of mature and functional NK cells from several different hESC and iPSC lines. Although different hESC and iPSC lines had varying efficiencies in hematopoietic development, all cell lines tested could produce functional NK cells. These methods can be used to generate enough cytotoxic NK cells to treat a single patient from fewer than 250,000 input hESCs/iPSCs. Additionally, this strategy provides a genetically amenable platform to study normal NK cell development and education in vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Embryonic stem cell trials for macular degeneration: a preliminary report
Schwartz, S. D., Hubschman, J.-P., Heilwell, G., Franco-Cardenas, V., Pan, C. K., Ostrick, R. M., Mickunas, E., Gay, R., Klimanskaya, I., & Lanza, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60028-2 · Cited by 1,409
Licensing of natural killer cells by host major histocompatibility complex class I molecules
Kim, S., Poursine-Laurent, J., Truscott, S. M., Lybarger, L., Song, Y.-J., Yang, L., French, A. R., Sunwoo, J. B., Lemieux, S., Hansen, T. H., et al. (2005) · Nature · doi:10.1038/nature03847 · Cited by 1,340
The promise of induced pluripotent stem cells in research and therapy
Robinton, D. A., & Daley, G. Q. (2012) · Nature · doi:10.1038/nature10761 · Cited by 1,111
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., Johnson, J. L., Singh, H., Hurton, L., Maiti, S. N., Huls, M. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030264 · Cited by 683
Self-citationExpansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W. H., & Campana, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3712 · Cited by 595
Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Le, C. T., Marsh, S. G. E., Geraghty, D., Spellman, S., Haagenson, M. D., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283051 · Cited by 591
Prospects for the use of NK cells in immunotherapy of human cancer
Ljunggren, H.-G., & Malmberg, K.-J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2073 · Cited by 543
Torikai, H., Reik, A., Liu, P.-Q., Zhou, Y., Zhang, L., Maiti, S., Huls, H., Miller, J. C., Kebriaei, P., Rabinovitch, B., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405365 · Cited by 528
Self-citationMrozek, E., Anderson, P., & Caligiuri, M. (1996) · Blood · doi:10.1182/blood.v87.7.2632.bloodjournal8772632 · Cited by 492
Hematopoietic and Endothelial Differentiation of Human Induced Pluripotent Stem Cells
Choi, K.-D., Yu, J., Smuga-Otto, K., Salvagiotto, G., Rehrauer, W. M., Vodyanik, M. A., Thomson, J. L., & Slukvin, I. I. (2009) · Stem Cells · doi:10.1002/stem.20080922 · Cited by 492
The promise and potential pitfalls of chimeric antigen receptors
Sadelain, M., Brentjens, R., & Rivière, I. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.009 · Cited by 467
A potential role for interleukin-15 in the regulation of human natural killer cell survival.
Carson, W. E., Fehniger, T. A., Haldar, S., Eckhert, K., Lindemann, M. J., Lai, C. F., Croce, C. M., Baumann, H., & Caligiuri, M. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119258 · Cited by 419
Ng, E. S., Davis, R. P., Azzola, L., Stanley, E. G., & Elefanty, A. G. (2005) · Blood · doi:10.1182/blood-2005-03-0987 · Cited by 408
Ng, E. S., Davis, R., Stanley, E. G., & Elefanty, A. G. (2008) · Nature Protocols · doi:10.1038/nprot.2008.42 · Cited by 325
Ledran, M. H., Krassowska, A., Armstrong, L., Dimmick, I., Renström, J., Lang, R., Yung, S., Santibanez-Coref, M., Dzierzak, E., Stojkovic, M., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.06.001 · Cited by 291
Woll, P. S., Grzywacz, B., Tian, X., Marcus, R. K., Knorr, D. A., Verneris, M. R., & Kaufman, D. S. (2009) · Blood · doi:10.1182/blood-2008-06-165225 · Cited by 268
Self-citationHuman Embryonic Stem Cell-Derived NK Cells Acquire Functional Receptors and Cytolytic Activity
Woll, P. S., Martin, C. H., Miller, J. S., & Kaufman, D. S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5095 · Cited by 233
Self-citationGeneration of T Cells from Human Embryonic Stem Cell-Derived Hematopoietic Zones
Timmermans, F., Velghe, I., Vanwalleghem, L., De Smedt, M., Van Coppernolle, S., Taghon, T., Moore, H. D., Leclercq, G., Langerak, A. W., Kerre, T., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803670 · Cited by 199
Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells
Kaufman, D. S. (2009) · Blood · doi:10.1182/blood-2009-03-191304 · Cited by 157
Self-citationT lineage differentiation from human embryonic stem cells
Galić, Z., Kitchen, S. G., Kacena, A., Subramanian, A., Burke, B. P., Cortado, R., & Zack, J. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604244103 · Cited by 148
Ni, Z., Knorr, D. A., Clouser, C. L., Hexum, M. K., Southern, P. J., Mansky, L. M., Park, I., & Kaufman, D. S. (2010) · Journal of Virology · doi:10.1128/jvi.01774-10 · Cited by 100
Self-citationHill, K. L., Obrtlíková, P., Alvarez, D. F., King, J. A. C., Keirstead, S. A., Allred, J. R., & Kaufman, D. S. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.01.001 · Cited by 90
Self-citationHuman embryonic stem cell-derived CD34+ cells function as MSC progenitor cells
Kopher, R. A., Penchev, V. R., Islam, M. S., Hill, K. L., Khosla, S., & Kaufman, D. S. (2010) · Bone · doi:10.1016/j.bone.2010.06.020 · Cited by 67
Self-citationPluripotent stem cell-derived natural killer cells for cancer therapy
Knorr, D. A., & Kaufman, D. S. (2010) · Translational research · doi:10.1016/j.trsl.2010.07.008 · Cited by 62
Self-citationTian, X., Hexum, M. K., Penchev, V. R., Taylor, R. J., Shultz, L. D., & Kaufman, D. S. (2009) · Stem Cells · doi:10.1002/stem.204 · Cited by 51
Self-citation
Cited by
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
Li, Y., Hermanson, D. L., Moriarity, B. S., & Kaufman, D. S. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.06.002 · Cited by 981
Self-citationCAR-NK cells: A promising cellular immunotherapy for cancer
Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
Metadata
- Authors
- Knorr, D. A., Ni, Z., Hermanson, D., Hexum, M. K., Bendzick, L., Cooper, L. J. N., Lee, D. A., & Kaufman, D. S.
- Venue
- Stem Cells Translational Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-03-20
- Volume
- 2
- Issue
- 4
- Pages
- 274-283
- ISSN
- 2157-6564 (ISSN-L)
- 2157-6580
- OpenAlex
- W2092166052
- Cited by
- 415
- References
- 28
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.